• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $INKT

    MiNK Therapeutics Inc.

    Subscribe to $INKT
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: minktherapeutics.com

    Peers

    $AGEN

    Recent Analyst Ratings for MiNK Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    1/24/2022$24.00 → $10.00Buy
    B. Riley Securities
    11/9/2021$24.00Buy
    B. Riley Securities
    11/9/2021$26.00Outperform
    Robert W. Baird
    11/9/2021Outperform
    William Blair
    11/9/2021$30.00Outperform
    Evercore ISI Group
    11/9/2021$26.00Outperform
    Baird
    See more ratings

    MiNK Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

      NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics ((MiNK, NASDAQ:INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases. Dr. Kadlec recently served as the U.S. Senate-confirmed Assistant

      10/31/24 9:15:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

      Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has entered into a stock purchase agreement to sell securities in a private placement financing (PIPE) for $5.8 million. This capital injection is e

      5/13/24 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    MiNK Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

      NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 982

      5/5/25 12:30:00 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET. "Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders," said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK The

      3/18/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

      NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada

      3/4/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

      NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today presented new translational data from its ongoing Phase 2 study of allo-iNKTs, agenT-797, at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The study evaluates agenT-797 in combination with botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastroesophageal cancer (NCT06251973). "We are encouraged by these latest data that demonstrate a powerful synergy between MiNK's allo-iNKT cell

      2/24/25 8:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

      NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal notice from Nasdaq confirming that the Company has regained compliance with both the minimum bid price and market value of listed securities requirements for continued listing on The Nasdaq Capital Market. As a result, MiNK now meets all Nasdaq Capital Market listing requirements, and the matter has been closed. About MiNK Therapeutics Mi

      2/20/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

      NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combinatio

      2/12/25 1:00:00 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

      NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium in San Francisco, California. "INKT cells play a pivotal role in reconstituting lymphocytes, establishing a robust and responsive immune environment to address the complexities of advanced cancers. Agenus' botensilimab/balstilimab combination (BOT/BAL) amplifies this effect by enhancing T-cel

      1/23/25 2:13:08 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

      NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium that will take place on January 23-25, 2025, in San Francisco, California. The poster presentation will highlight the ongoing Phase 2 study of agenT-797 in combination with Agenus' botensilimab/balstilimab in patients with refractory gastric cancer.

      12/18/24 9:45:42 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

      NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the third quarter 2024. MiNK will host a conference call and webcast at 8:30 a.m. ET. "Our progress this quarter reflects MiNK's commitment to advancing effective and scalable therapies in cancer and immune-mediated diseases," said Jennifer Buell, PhD, Chief Executive Officer of MiNK Therapeutics. "We have continued to expand our iNKT ce

      11/14/24 7:00:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

      NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID:

      11/11/24 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    MiNK Therapeutics Inc. SEC Filings

    See more
    • SEC Form DEF 14A filed by MiNK Therapeutics Inc.

      DEF 14A - MiNK Therapeutics, Inc. (0001840229) (Filer)

      4/30/25 4:08:04 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by MiNK Therapeutics Inc.

      PRE 14A - MiNK Therapeutics, Inc. (0001840229) (Filer)

      4/18/25 4:30:05 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by MiNK Therapeutics Inc.

      10-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

      3/18/25 5:03:49 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

      3/18/25 7:30:11 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by MiNK Therapeutics Inc.

      8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

      1/21/25 4:52:22 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by MiNK Therapeutics Inc.

      DEF 14A - MiNK Therapeutics, Inc. (0001840229) (Filer)

      12/20/24 4:17:58 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by MiNK Therapeutics Inc.

      PRE 14A - MiNK Therapeutics, Inc. (0001840229) (Filer)

      12/6/24 5:09:33 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by MiNK Therapeutics Inc.

      10-Q - MiNK Therapeutics, Inc. (0001840229) (Filer)

      11/14/24 4:05:25 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

      11/14/24 7:00:34 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

      10/31/24 9:15:08 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    MiNK Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Agenus Inc bought $25,270 worth of shares (22,975 units at $1.10), increasing direct ownership by 0.11% to 21,772,863 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      10/16/23 5:49:39 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Inc bought $16,380 worth of shares (15,001 units at $1.09), increasing direct ownership by 0.07% to 21,749,888 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      10/6/23 4:26:25 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    MiNK Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities reiterated coverage on MiNK Therapeutics with a new price target

      B. Riley Securities reiterated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $10.00 from $24.00 previously

      1/24/22 8:57:46 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on MiNK Therapeutics with a new price target

      B. Riley Securities initiated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $24.00

      11/9/21 7:57:17 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on MiNK Therapeutics with a new price target

      Robert W. Baird initiated coverage of MiNK Therapeutics with a rating of Outperform and set a new price target of $26.00

      11/9/21 7:17:32 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on MiNK Therapeutics

      William Blair initiated coverage of MiNK Therapeutics with a rating of Outperform

      11/9/21 7:04:35 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI Group initiated coverage on MiNK Therapeutics with a new price target

      Evercore ISI Group initiated coverage of MiNK Therapeutics with a rating of Outperform and set a new price target of $30.00

      11/9/21 7:02:24 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Baird initiated coverage on MiNK Therapeutics with a new price target

      Baird initiated coverage of MiNK Therapeutics with a rating of Outperform and set a new price target of $26.00

      11/9/21 4:27:59 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    MiNK Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MiNK Therapeutics Inc.

      SC 13G - MiNK Therapeutics, Inc. (0001840229) (Subject)

      5/22/24 4:33:15 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by MiNK Therapeutics Inc.

      SC 13D - MiNK Therapeutics, Inc. (0001840229) (Subject)

      2/14/24 6:05:43 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by MiNK Therapeutics Inc. (Amendment)

      SC 13D/A - MiNK Therapeutics, Inc. (0001840229) (Subject)

      5/26/23 5:03:14 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by MiNK Therapeutics Inc. (Amendment)

      SC 13D/A - MiNK Therapeutics, Inc. (0001840229) (Subject)

      5/3/23 5:23:56 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by MiNK Therapeutics Inc.

      SC 13G - MiNK Therapeutics, Inc. (0001840229) (Subject)

      2/14/22 4:06:27 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by MiNK Therapeutics Inc.

      SC 13D - MiNK Therapeutics, Inc. (0001840229) (Subject)

      10/28/21 4:30:32 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    MiNK Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kadlec Robert Peter was granted 1,536 shares, increasing direct ownership by 125% to 2,764 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      3/5/25 4:05:15 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Behner Peter was granted 1,849 shares, increasing direct ownership by 14% to 15,209 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      3/5/25 4:05:14 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wiinberg Ulf was granted 1,593 shares, increasing direct ownership by 11% to 16,007 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      3/5/25 4:05:11 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Corvese Brian was granted 2,033 shares, increasing direct ownership by 5% to 44,657 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      3/5/25 4:05:03 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Ryan Barbara was granted 2,019 shares, increasing direct ownership by 13% to 17,048 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      3/5/25 4:05:05 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kadlec Robert Peter was granted 12,286 shares (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      12/9/24 4:10:04 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Kadlec Robert Peter

      3 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      12/9/24 4:05:06 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Ryan Barbara was granted 24,229 shares, increasing direct ownership by 19% to 150,336 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      12/3/24 10:44:42 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Corvese Brian was granted 24,400 shares, increasing direct ownership by 6% to 426,283 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      12/3/24 10:44:13 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Behner Peter was granted 20,987 shares, increasing direct ownership by 19% to 133,634 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      12/3/24 10:38:20 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    MiNK Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

      NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 982

      5/5/25 12:30:00 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET. "Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders," said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK The

      3/18/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

      NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada

      3/4/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

      NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the third quarter 2024. MiNK will host a conference call and webcast at 8:30 a.m. ET. "Our progress this quarter reflects MiNK's commitment to advancing effective and scalable therapies in cancer and immune-mediated diseases," said Jennifer Buell, PhD, Chief Executive Officer of MiNK Therapeutics. "We have continued to expand our iNKT ce

      11/14/24 7:00:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

      NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID:

      11/11/24 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Reports Second Quarter 2024 Results and Business Update

      Expanded Access to AgenT-797 in Severe ARDS Reinforces Clinical Efficacy; Data Highlighted at ATS 2024 Annual MeetingPhase 2 Study in 2L Gastric Cancer Advances; Early Clinical Data to be Presented at Upcoming Medical ConferencePhase 1 Study in GvHD on Track for Activation in 2Q 2024 NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the second quarter 2024. MiNK executives will host a conference ca

      8/13/24 7:00:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

      NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 4

      8/1/24 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Reports First Quarter 2024 Results

      Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS)AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call a

      5/14/24 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

      NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (U.S. – NY), (800) 715-9871 (U.S. & Canada)

      4/30/24 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Reports Fourth Quarter and Year-End 2023 Results

      Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapiesPublished clinical data in Nature Communications and Oncogene demonstrating clinical activity of allo-iNKTs, agenT-797, in solid tumors and severe acute respiratory distress NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) --  MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-

      3/21/24 7:00:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care